Barry Singer, MD, The MS Center for Innovations in Care, St. Louis, MO, shares his highlights from the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023, themed “MS: going viral”. One of the most discussed topics at the meeting was the role of Epstein Barr virus (EBV) in the development of multiple sclerosis (MS). Earlier last year, a study by Dr Ascherio showed that exposure to EBV seems to be a very important trigger for developing MS. Potential therapeutic strategies targeting EBV were discussed, including vaccines already being tested in clinical trials. At ACTRIMS, there was also data presented on human immunodeficiency virus (HIV), showing that the incidence of MS is lower in people with HIV. This interview took place at the ACTRIMS Forum 2023 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
BS has received research grant support from AbbVie, Biogen, Bristol Myers Squibb, Greenwich Biosciences, Novartis and Sanofi and consulting and/or speaking fees from Alexion, Biogen, Bristol Myers Squibb, Cigna, Cycle, EMD Serono, Genentech, Horizon, Janssen, Novartis, Octave Bioscience, Roche, Sanofi and TG Therapeutics.